ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1734

Intra‑articular Liraglutide Halts Osteoarthritis Progression, Surpassing Dexamethasone in Synovial and Cartilage Protection
Abstract Number: 0481

Intracellular Methotrexate Polyglutamate Profiles Do Not Correlate with Early Clinical Response in Treatment-Naïve Rheumatoid Arthritis: A Prospective Study
Abstract Number: 1971

Intracranial Arterial Stenosis in Antiphospholipid Syndrome: A Neglected Vascular Involvement?
Abstract Number: 1577

Intravenous cyclophosphamide in the treatment of progressive interstitial lung diseases associated with systemic sclerosis: a prospective randomized trial versus placebo (SCLEROCYC).
Abstract Number: 0740

Intravenous versus subcutaneous administration of Tocilizumab in aortitis associated with giant cell arteritis: multicenter open-label study of 196 patients
Abstract Number: 0386

Introducing the Multidimensional Pain Inventory as a Comprehensive Tool or Assessing Pain in Patients With Axial Spondyloarthritis
Abstract Number: 2231

Inverse Correlation Between Neutrophil Activation and Rheumatoid Factor Concentrations in Rheumatoid Arthritis (RA)
Abstract Number: 0515

Inverse Correlation Between Type I Interferon Pathway Activation And Unstimulated Whole Salivary Flow In Sicca Patients
Abstract Number: 1067

Investigating Barriers to Care through Childhood Opportunity, Social Vulnerability, Area Deprivation, and Distance to Care in Pediatric Localized Scleroderma
Abstract Number: 0188

Investigating Canadians’ information needs related to lupus: A Google Trends analysis of online search query data
Abstract Number: 2018

Investigating Epidemiology, Clinical associations, and Outcomes of Uveitis: A Retrospective Cohort Study
Abstract Number: 1902

Investigating Factors Associated With Respiratory Syncytial Virus Vaccination and Breakthrough Infection Among Patients With Systemic Autoimmune Rheumatic Diseases
Abstract Number: 2493

Investigating scoring systems to measure clinically relevant changes in systemic sclerosis-related finger acro-osteolysis over time, as assessed in serial hand radiographs
Abstract Number: 1280

Investigating the Association Between SARS-CoV-2 Infection, COVID-19 Vaccination, and Autoimmune Diseases in a Pediatric Population: A comprehensive analysis
Abstract Number: 1285

Investigating the Relationship Between Brain Injury Markers and Brain Volume in Children with Systemic Lupus Erythematosus and Healthy Controls

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].